- The FDA has approved 8 GLP-1-based active ingredients since 2005. As of November 2026, semaglutide, tirzepatide, liraglutide, dulaglutide and orforglipron are sold, plus two insulin combinations.1,2
- The newest is orforglipron (Foundayo), a daily tablet for weight management approved on April 1, 2026. Liraglutide is the only one with generics on the market.1
- Retatrutide, CagriSema and survodutide have published phase 3 results but are not approved.3–5
A GLP-1 drug activates the receptor for GLP-1, a gut hormone that boosts insulin after meals, slows the stomach and reduces appetite. Some newer drugs also act on other hormone receptors. Tirzepatide, for example, acts on both GIP and GLP-1 receptors. For how they work, see what is GLP-1?
Every GLP-1 drug approved in the US
We checked each product's status in the FDA's Drugs@FDA database and its current label on DailyMed in November 2026. "Approved uses" are the label's indications, in short form.
| Generic (brand) | Company | Form | Approved uses (US label) | First approved |
|---|---|---|---|---|
| Semaglutide (Ozempic) | Novo Nordisk | Weekly injection | Type 2 diabetes; lowering heart risk in type 2 diabetes with heart disease; lowering kidney and heart-death risk in type 2 diabetes with chronic kidney disease | 2017 |
| Semaglutide (Wegovy injection) | Novo Nordisk | Weekly injection, doses up to 7.2 mg | Weight management in adults and children 12+; lowering heart risk in adults with heart disease and obesity or overweight; MASH liver disease with moderate to advanced fibrosis (accelerated approval) | 2021 |
| Semaglutide (Wegovy tablets) | Novo Nordisk | Daily tablet | Weight management in adults; lowering heart risk in adults with heart disease and obesity or overweight | 2025 |
| Semaglutide (Rybelsus, Ozempic tablets) | Novo Nordisk | Daily tablet | Type 2 diabetes; lowering heart risk in type 2 diabetes at high risk | 2019 |
| Tirzepatide (Mounjaro) | Eli Lilly | Weekly injection | Type 2 diabetes in adults and children 10+; lowering heart risk in type 2 diabetes at high risk | 2022 |
| Tirzepatide (Zepbound) | Eli Lilly | Weekly injection | Weight management in adults; moderate to severe sleep apnea with obesity | 2023 |
| Orforglipron (Foundayo) | Eli Lilly | Daily tablet | Weight management in adults | 2026 |
| Dulaglutide (Trulicity) | Eli Lilly | Weekly injection | Type 2 diabetes in adults and children 10+; lowering heart risk in type 2 diabetes | 2014 |
| Liraglutide (Victoza) | Novo Nordisk | Daily injection | Type 2 diabetes in adults and children 10+; lowering heart risk in type 2 diabetes with heart disease | 2010 |
| Liraglutide (Saxenda) | Novo Nordisk | Daily injection | Weight management in adults, and children 12+ over 60 kg with obesity | 2014 |
| Liraglutide (generic) | Hikma, Teva, Biocon and others | Daily injection | Versions labeled for type 2 diabetes and versions labeled for weight management | 2024 |
| Insulin degludec + liraglutide (Xultophy 100/3.6) | Novo Nordisk | Daily injection | Type 2 diabetes in adults | 2016 |
| Insulin glargine + lixisenatide (Soliqua 100/33) | Sanofi | Daily injection | Type 2 diabetes in adults | 2016 |
No longer sold, or no current label
| Generic (brand) | Company | First approved | Status, November 2026 |
|---|---|---|---|
| Exenatide (Byetta), twice-daily injection | AstraZeneca | 2005 | Listed as discontinued in Drugs@FDA |
| Exenatide extended-release (Bydureon, Bydureon BCise) | AstraZeneca | 2012 (BCise 2017) | Listed as discontinued in Drugs@FDA |
| Exenatide (generic) | Amneal | 2024 | Listed as discontinued in Drugs@FDA |
| Albiglutide (Tanzeum) | GlaxoSmithKline | 2014 | Listed as discontinued in Drugs@FDA |
| Lixisenatide alone (Adlyxin) | Sanofi | 2016 | No current label on DailyMed; lixisenatide is still sold inside Soliqua |
A product listed as discontinued may still turn up in an old prescription or pharmacy system. If you are on one, your pharmacist can confirm whether it is available.
Which GLP-1 drugs are approved for weight loss?
Five products carry a weight-management indication: Wegovy (injection and tablets), Zepbound, Saxenda and generic liraglutide labeled for weight management, and Foundayo.2 Ozempic, Mounjaro, Rybelsus, Trulicity and Victoza are approved for type 2 diabetes, not weight loss, even though people with diabetes lose weight on them. Several labels, including Wegovy, Saxenda and Foundayo, say not to use them together with another GLP-1 drug. For how they compare, see Ozempic vs Wegovy vs Mounjaro vs Zepbound and semaglutide vs tirzepatide.
Which GLP-1 drugs are pills?
- Rybelsus and Ozempic tablets (oral semaglutide, type 2 diabetes). Both names appear on one US label. Rybelsus comes in 3, 7 and 14 mg and Ozempic tablets in 1.5, 4 and 9 mg. The label says to take them once daily on an empty stomach with up to 4 ounces of water.2
- Wegovy tablets (oral semaglutide), approved in December 2025.1 The label's maintenance dose is 25 mg once daily, for weight management and heart risk.2
- Foundayo (orforglipron). The label says to take it once daily, with or without food.2
See GLP-1 pills, oral semaglutide for weight loss and orforglipron trial results.
Is there a generic GLP-1?
Liraglutide is the only GLP-1 with generics on the US market. Drugs@FDA lists the first generic liraglutide approval in December 2024 (Hikma), followed by others from Teva, Biocon and more. DailyMed carries generic labels for type 2 diabetes and for weight management.1,2
For semaglutide, Drugs@FDA shows one generic injection (Apotex) with tentative approval in April 2026. Tentative approval means the FDA found it meets the scientific standard, but it cannot be sold yet, usually because of patents. There is no generic tirzepatide.1 Compounded versions are not FDA approved; see compounded semaglutide and tirzepatide.
New GLP-1 drugs in late-stage trials
None of these is FDA approved. None appeared in Drugs@FDA in November 2026.1 Weight loss below is the average from each trial's main analysis, in adults with obesity or overweight.
| Drug (company) | What it acts on | Latest published trial | Average weight change |
|---|---|---|---|
| Retatrutide (Eli Lilly), weekly injection | GIP, GLP-1 and glucagon receptors | Phase 3 TRIUMPH-1, 2,339 adults without diabetes, 80 weeks | −25.0% on 12 mg vs −3.9% placebo |
| CagriSema: cagrilintide + semaglutide (Novo Nordisk), weekly injection | Amylin and GLP-1 receptors | Phase 3a REDEFINE 1, 3,417 adults without diabetes, 68 weeks | −20.4% vs −3.0% placebo |
| Survodutide (Boehringer Ingelheim), weekly injection | Glucagon and GLP-1 receptors | Phase 3 SYNCHRONIZE-1, 725 adults without diabetes, 76 weeks | −13.0% on 6.0 mg vs −5.4% placebo |
| Maridebart cafraglutide, MariTide (Amgen), injection every 4 weeks | Activates GLP-1 receptors and blocks GIP receptors (antibody-peptide drug) | Phase 2, 465 adults with obesity, 52 weeks | −12.3% to −16.2% vs −2.5% placebo |
| Amycretin (Novo Nordisk), weekly injection | GLP-1 and amylin receptors | Phase 1b/2a, single US center, up to 36 weeks | −22.0% on 20 mg vs +1.9% placebo at 36 weeks |
Stomach side effects were common in all five. In REDEFINE 1 they affected 79.6% on CagriSema vs 39.9% on placebo, and in SYNCHRONIZE-1, 89.7% on survodutide 6.0 mg vs 47.9% on placebo.4,5 The amycretin and MariTide results are from smaller, earlier trials, so their numbers are less certain. For more on the furthest along, see retatrutide trial results.
Common questions
What are the GLP-1 medications?
The FDA has approved 8 GLP-1-based active ingredients since 2005. As of November 2026, those with current US labels include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda and generics), dulaglutide (Trulicity), orforglipron (Foundayo), and two insulin combinations, Xultophy and Soliqua.
What is the newest GLP-1 drug?
Orforglipron (Foundayo), a once-daily tablet from Eli Lilly for weight management in adults, was approved by the FDA on April 1, 2026, according to the Drugs@FDA database. Wegovy tablets (oral semaglutide 25 mg) were approved in December 2025.
Is there a generic GLP-1 drug?
Yes, liraglutide. The FDA's database lists generic liraglutide approvals from December 2024, with versions labeled for type 2 diabetes and for weight management. As of November 2026, a generic semaglutide injection has only tentative FDA approval, and there is no generic tirzepatide.
Which GLP-1 drugs come as a pill?
Three: Rybelsus and Ozempic tablets (oral semaglutide for type 2 diabetes), Wegovy tablets (oral semaglutide for weight management and heart risk) and Foundayo (orforglipron for weight management). All are taken once daily.
What new GLP-1 drugs are coming?
Phase 3 results have been published for retatrutide, which led to 25.0% average weight loss on 12 mg vs 3.9% on placebo over 80 weeks in TRIUMPH-1, CagriSema (20.4% vs 3.0% over 68 weeks in REDEFINE 1) and survodutide. None was FDA approved as of November 2026.
Sources
- US FDA. Drugs@FDA database, application and marketing status records, accessed through openFDA, November 2026. Search the same records at Drugs@FDA.
- US prescribing information on DailyMed (2025–2026 versions, checked November 2026): OZEMPIC, WEGOVY injection and tablets, RYBELSUS and OZEMPIC tablets, MOUNJARO, ZEPBOUND, VICTOZA, SAXENDA, TRULICITY, FOUNDAYO, XULTOPHY 100/3.6, SOLIQUA 100/33, BYETTA; generic liraglutide labels via DailyMed search.
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026;395(18):1781-1793. doi:10.1056/NEJMoa2604169 · PubMed
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081 · PubMed
- le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026;395(8):776-787. doi:10.1056/NEJMoa2600751 · PubMed
- Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. doi:10.1056/NEJMoa2504214 · PubMed
- Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10499):149-162. doi:10.1016/S0140-6736(25)01185-7 · PubMed
